TRACON Pharmaceuticals, Inc. - Common Stock (TCON)

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares (ADSs) from the Nasdaq Capital Market. The news triggered an immediate and dramatic 62.5% plunge in the company's stock during premarket

TCON stock results show that TRACON Pharma beat analyst estimates for earnings per share the second quarter of 2024.

TCON stock results show that TRACON Pharma missed analyst estimates for earnings per share the first quarter of 2024.

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!

Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals.

Explore three penny stocks primed for significant growth, backed by Strong Buy ratings from Wall Street. Play it high-risk.

Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ: AGEN) declined 17% to $0.4181 on Monday.

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.